HK1103023A1 - Sustained release formulations - Google Patents

Sustained release formulations

Info

Publication number
HK1103023A1
HK1103023A1 HK07108780.0A HK07108780A HK1103023A1 HK 1103023 A1 HK1103023 A1 HK 1103023A1 HK 07108780 A HK07108780 A HK 07108780A HK 1103023 A1 HK1103023 A1 HK 1103023A1
Authority
HK
Hong Kong
Prior art keywords
sustained release
release formulations
formulations
sustained
release
Prior art date
Application number
HK07108780.0A
Other languages
English (en)
Inventor
Merrill S Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1103023A1 publication Critical patent/HK1103023A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK07108780.0A 2004-04-23 2007-08-13 Sustained release formulations HK1103023A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56524704P 2004-04-23 2004-04-23
PCT/US2005/014254 WO2005105057A1 (en) 2004-04-23 2005-04-25 Sustained release formulations

Publications (1)

Publication Number Publication Date
HK1103023A1 true HK1103023A1 (en) 2007-12-14

Family

ID=34967842

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07108780.0A HK1103023A1 (en) 2004-04-23 2007-08-13 Sustained release formulations
HK15100510.4A HK1200092A1 (en) 2004-04-23 2015-01-16 Sustained release formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15100510.4A HK1200092A1 (en) 2004-04-23 2015-01-16 Sustained release formulations

Country Status (16)

Country Link
US (2) US7323169B2 (ko)
EP (1) EP1750683B1 (ko)
JP (3) JP5036533B2 (ko)
KR (1) KR101201638B1 (ko)
CN (2) CN103920162B (ko)
AU (1) AU2005237542B2 (ko)
CA (1) CA2563185C (ko)
DK (1) DK1750683T3 (ko)
ES (1) ES2400687T3 (ko)
HK (2) HK1103023A1 (ko)
IL (1) IL178596A (ko)
PL (1) PL1750683T3 (ko)
PT (1) PT1750683E (ko)
SI (1) SI1750683T1 (ko)
WO (1) WO2005105057A1 (ko)
ZA (1) ZA200609401B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1750683T1 (sl) * 2004-04-23 2013-04-30 Amgen Inc. M/S 27-4-A, Amgen Inc. Formulacije s podaljĺ anim sproĺ äśanjem
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
MX2008001468A (es) * 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
EP1993606A4 (en) * 2006-02-15 2010-01-20 Gammacan Ltd VITILIGO PLASMA IMMUNOGLOBULINS FOR THE TREATMENT OF MELANOMA
AU2007275638B2 (en) * 2006-07-21 2014-01-16 Amgen Inc. Method of detecting and/ or measuring hepcidin in a sample
WO2013106175A1 (en) * 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
EP2235058A2 (en) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
US20090214654A1 (en) * 2008-02-21 2009-08-27 Isenburg Jason C Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
KR20140145947A (ko) 2011-03-16 2014-12-24 암젠 인크 Nav1.3과 nav1.7의 유효한 선별적 저해제
WO2012158944A1 (en) 2011-05-18 2012-11-22 Vatrix Medical, Inc. Coated balloons for blood vessel stabilization
EP3907237A1 (en) 2012-12-20 2021-11-10 Amgen Inc. Apj receptor agonists and uses thereof
EP2951205B1 (en) 2013-02-01 2021-08-11 Santa Maria Biotherapeutics, Inc. Anti-activin-a compounds for the treatment of ovarian cancer
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1.7之強效及選擇性抑制劑
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
US11654114B2 (en) * 2017-06-07 2023-05-23 Egy-Nano Pharma, Lp Oral prolonged drug delivery platforms
WO2020027881A1 (en) 2018-08-03 2020-02-06 Nectero Medical, Inc. Purified pentagalloyl glucose and devices for delivery
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
GB929405A (en) 1958-12-22 1963-06-19 Upjohn Co Processes for the encapsulation of particles
CH498653A (fr) 1968-03-29 1970-11-15 Kobayashi Takehiko Procédé d'encapsulation de matières hydrophobes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP2744572B2 (ja) * 1993-02-17 1998-04-28 鐘紡株式会社 ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法
JPH06345668A (ja) * 1993-06-07 1994-12-20 Shibayagi:Kk 感染防御組成物およびその用途
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
WO1998010649A1 (en) 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6531154B1 (en) * 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
CA2296654A1 (en) * 1997-07-23 1999-02-04 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
ATE281155T1 (de) * 1998-04-20 2004-11-15 Genzyme Corp Medikamentöse verabreichung von proteinen aus polymergemischen
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
CA2389304A1 (en) 1999-11-01 2001-05-10 Corinne S. Lengsfeld Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
WO2002067966A1 (en) * 2001-02-22 2002-09-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
JP5013152B2 (ja) * 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US20040142048A1 (en) * 2002-02-22 2004-07-22 Morre Dorothy M. Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer
CN1668212A (zh) * 2002-07-26 2005-09-14 帝斯曼知识产权资产管理有限公司 包含乳铁蛋白的组合物
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
SI1750683T1 (sl) * 2004-04-23 2013-04-30 Amgen Inc. M/S 27-4-A, Amgen Inc. Formulacije s podaljĺ anim sproĺ äśanjem

Also Published As

Publication number Publication date
PT1750683E (pt) 2013-01-25
JP5829870B2 (ja) 2015-12-09
EP1750683B1 (en) 2013-01-09
US7732399B2 (en) 2010-06-08
US7323169B2 (en) 2008-01-29
US20070292506A1 (en) 2007-12-20
CN1997356A (zh) 2007-07-11
HK1200092A1 (en) 2015-07-31
KR101201638B1 (ko) 2012-11-15
PL1750683T3 (pl) 2013-05-31
US20050271722A1 (en) 2005-12-08
CA2563185C (en) 2010-04-20
KR20070026457A (ko) 2007-03-08
JP2012046520A (ja) 2012-03-08
JP2007534698A (ja) 2007-11-29
ZA200609401B (en) 2008-05-28
CN103920162A (zh) 2014-07-16
WO2005105057A1 (en) 2005-11-10
CN103920162B (zh) 2017-07-11
DK1750683T3 (da) 2013-04-15
SI1750683T1 (sl) 2013-04-30
ES2400687T3 (es) 2013-04-11
AU2005237542A1 (en) 2005-11-10
EP1750683A1 (en) 2007-02-14
AU2005237542B2 (en) 2009-12-17
JP2012036194A (ja) 2012-02-23
JP5036533B2 (ja) 2012-09-26
IL178596A (en) 2012-06-28
CA2563185A1 (en) 2005-11-10
IL178596A0 (en) 2007-02-11

Similar Documents

Publication Publication Date Title
HK1200092A1 (en) Sustained release formulations
IL184460A0 (en) Sustained release pharmaeutical formulations
EP1765385A4 (en) IMPORTS COMPOSITION WITH DELAYED RELEASE
EP1714643A4 (en) PREPARATION WITH DELAYED RELEASE
GB2424581B (en) Formulations
IL181265A0 (en) Stabilizing formulations
ZA200801158B (en) Sustained drug release composition
GB0406819D0 (en) Controlled release compositions
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
ZA200707654B (en) Formulations
EP1951693A4 (en) SOLID FORMULATIONS
IL177328A0 (en) Controlled release formulations
GB0406048D0 (en) Drug formulations
GB0417248D0 (en) Formulations
IL179208A0 (en) Intereferon formulations
GB0417226D0 (en) Formulations
GB0426293D0 (en) Novel formulations
GB0426295D0 (en) Novel formulations
GB0420821D0 (en) Novel formulations
GB0427248D0 (en) Novel formulations
GB0427247D0 (en) Novel formulations
GB0427245D0 (en) Novel formulations
GB0427244D0 (en) Novel formulations
GB0420820D0 (en) Novel formulations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190425